✉ Email this page to a colleague
« Back to Dashboard
Namilumab is an investigational drug.
There have been 7 clinical trials for Namilumab. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Arthritis, Rheumatoid, Arthritis, and Sarcoidosis. The leading clinical trial sponsors are Takeda, Kinevant Sciences GmbH, and [disabled in preview].
There are two US patents protecting this investigational drug and twelve international patents.
Recent Clinical Trials for Namilumab
|A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis||Kinevant Sciences GmbH||Phase 2|
|A Study to Assess the Safety, Tolerability, and Efficacy of Namilumab in Participants With Active Cardiac Sarcoidosis||Kinevant Sciences GmbH||Phase 2|
|Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate||Takeda||Phase 2|
Top disease conditions for Namilumab
Top clinical trial sponsors for Namilumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Namilumab||See Plans and Pricing||Cholestosome vesicles for incorporation of molecules into chylomicrons||THERASYN SENSORS, INC. (Eggertsville, NY)||See Plans and Pricing|
|Namilumab||See Plans and Pricing||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Namilumab||Australia||AU2014236559||2033-03-14||See Plans and Pricing|
|Namilumab||Brazil||BR112015022936||2033-03-14||See Plans and Pricing|
|Namilumab||Canada||CA2905108||2033-03-14||See Plans and Pricing|
|Namilumab||China||CN105164143||2033-03-14||See Plans and Pricing|
|Namilumab||European Patent Office||EP2970369||2033-03-14||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|